STREAM (Standardised Treatment Regimens of Anti-tuberculosis drugs for Multidrug-Resistant Tuberculosis) Stage 1 demonstrated non-inferior efficacy of a short regimen for rifampicin-resistant TB (RR-TB) compared to a long regimen as recommended by the World Health Organization. This study analyzed factors associated with a definite or probable failure or relapse (FoR) event in participants receiving the short regimen. The factors associated with FoR outcomes identified in this study should be considered when determining the optimal shortened treatment regimen.
Published: August 1, 2022
Sign up to receive our monthly Research Roundup email, which offers a selection of new public health research from major journals.
Recent Abstracts
Report on Legal Framework Assessment on Civil Registration, Vital Statistics and Identification Management…
Integrated Use of Low-Cost Sensors to Strengthen Air Quality Management
Prioritizing Children: Environmental Health Indicators for China
Racial Disparities in United States Overdose Rates
Overdose Prevention Centers
Access to Naloxone to Reduce Overdose Deaths
Access to Safe Use Supplies for Less Harmful Drug Use
Medications for Opioid Use Disorders Prevent Overdose Deaths
Creating Safe Care: Supporting Pregnant and Parenting People Who Use Drugs
How the “Are We Drinking Ourselves Sick?” Communication Campaign Built Support for Policy…